**Title: The successful treatment of metastatic androgen receptor positive tumours of parotid origin with androgen receptor blockade and immunotherapy**

**Authors: Angus G Dalgleish1#, Silvana Di Palma2, Kannon Nathan**3**, Barry Powell1, Nirav Patel1 and Alberto Fusi1**

1St George's University Hospital, London, U.K.

2 Royal Surrey County Hospital, Guilford, UK

3 Kent Oncology Centre, Canterbury, UK

Corresponding Author: Prof. Angus Dalgleish - Infection & Immunity Research Centre - St George's, University of London, Cranmer Terrace, London, SW17 0RE, UK – Email: dalgleis@sgul.ac.uk

Dear Editor,

 Malignant parotid tumours are heterogeneous and diverse, ranging from indolent slow growing adenoid cystic to rapidly progressive salivary duct carcinoma [1]. The current treatment is surgery eventually followed by radiotherapy to prevent local recurrence [2]. Metastatic disease outside the draining lymph nodes often includes numerous and widespread bony metastases. Standard chemotherapy includes platinum-based regimens and bisphosphonate in case of bone metastases. The response rate is in the range of 30% with a very limited life expectancy with most of the patients not being alive within a year from the diagnosis of metastatic disease [3].

**Case reports**

**Index case**

A 36 year old man presented in December 2015 with a right axillary mass which was biopsied and turned out to be a metastatic oncocytic tumour. In January 2016 he had a right axillary dissection followed by adjuvant radiotherapy and in June 2016 a complete clearance of the lymph nodes in the right neck for further recurrence. Three months later he presented with multiple lytic lesions throughout his bony spine and pelvis (Figure 1a). Three samples from the left iliac wing confirmed small deposits of apocrine/oncocytic carcinoma consistent with metastases. The specialist MDT recommended a platinum-based first line treatment and he was commenced with carboplatin and paclitaxel in November 2016. At the same time he was started on Zoledronic acid.

After four courses of chemotherapy a re-assessment showed marked increase in both the number and size of his original bone lesions (Figure 1b).

Review of the literature showed that some of these tumours were noted to be androgen-receptor positive[4] and a review of his pathology confirmed that he had very strong androgen receptor (AR) expression. Having found a case report of a response to Abiraterone in a patient with a similar condition[5], he was commenced on Abiraterone in April 2017. After two months on treatment a disease re-assessment showed a partial response with marked healing of all his bone lesions (Figure 1c).

 As he was a very young man there was concern that the Abiraterone might not be a long lasting treatment. Based on a case report [6] Pembrolizumab was therefore introduced. The original report does not document PD-L1 expression and this patient was essentially negative on testing. He received Pembrolizumab for approximately 9 months before stopping due to toxicity. The Abiraterone was continued and eventually stopped in February 2018 when the scans suggested a complete response (Figure 1d).

**Patient 2**

A 69 year old gentleman presented with a right parotid mass in January 2016 which was fully resected and shown to be an adenocarcinoma. In July 2017 he presented with a right trigeminal nerve metastatic deposit and a re-staging scan showed that he had multiple bone metastases and retroperitoneal lymph nodes. The bone metastases were biopsied and confirmed adenocarcinoma, in keeping with metastatic salivary gland tumour. He was started on Zoledronic acid, Gemcitabine and on the investigational immunotherapeutic agent IMM-101 on a Named Patient Program [7]. His original histology was re-assessed for AR expression, and found to be strongly positive. He was not approved for Abiraterone but he was considered eligible for Bicalutamide which he commenced in October 2017. This led to a significant clinical improvement and a complete response to treatment which is ongoing 9 months later.

**Patient 3**

A 30 year old gentleman first presented in 1976 with a pleomorphic adenoma of the left parotid which was treated with surgery. He recurred 33 years later in 2009 with a left-sided adenopathy, again treated with surgery. Two years afterwards he presented with a thick melanoma on his left shoulder and had adjuvant BCG within a clinical study. In September 2016 a CT scan showed widespread bone metastases with early cauda equine compression at L2 (Figure a, d). He had radiotherapy to L1-L3 for 20Gy in 5 fractions and a L2 vertebroplasty afterwards for ongoing pain. A left iliac crest lesion was biopsied and showed metastatic pleomorphic adenoma. The tumour was found to be strongly positive for AR (Figure 4) and he was therefore commenced on Bicalutamide in May 2017. Within two months of starting Bicalutamide, a PET scan showed an initial response to treatment (Figure 3 b, e). Because of ongoing back pain which required further radiotherapy to T12 he was also commenced on Leuprorelin acetate three monthly. Following this, a recent scan showed further evidence of bone healing (Figure 3 c, f).

**Patient 4**

This 54 year old man presented in October 2015 with a lump in his right axilla which was found to be consistent with a metastatic ductal carcinoma likely of parotid origin. In April 2017 he was found to have secondaries in the brain as well as in the lungs and bones. He was given whole brain radiotherapy in May 2017 and carboplatin and paclitaxel afterwards which he completed in August 2017 with some minor response to treatment. He was started at the same time with Zoledronic acid. A re-assessment in December 2017 showed ongoing benefit in the brain, but a significant progression of the lung (Figure 5a, 5d) and bone.

Once again the histology was reassessed and found to be strongly positive for AR expression. He was therefore started with Bicalutamide in January 2018 with regression in the number and size of pulmonary and brain metastases and healing of the bone metastases (Figure 5b, 5e). The benefit is still ongoing after a year on treatment (Figure 5c, 5f).

**Discussion**

The main point from these cases is that a specialist MDT in a leading cancer centre recommended a platinum based chemotherapy as recognised therapy. This is in spite of literature reporting an association with AR positivity for several years [4], together with the anecdotal response to anti-AR therapy including Abiraterone [5].

A sole case report of a response to Pembrolizumab in a patient with metastatic apocrine carcinoma with similar distribution of the disease led to it being added to Abiraterone with further reduction in disease progression. A cohort of patients with advanced PD-L1-positive salivary gland carcinoma was enrolled in the nonrandomized phase Ib trial and treated with of Pembrolizumab. Three patients achieved a partial response (there were no CRs) and additional 12 patients had a stability of disease for a disease control rate (CR+PR+SD) of 58% [9].

It is of interest that the second patient was already on a non-specific immunotherapy (IMM-101) and that the third patient had received a BCG based protocol for his metastatic melanoma. This raises the possibility that AR blockade may be even more effective when combined with immunotherapy.

**References:**

[1] [Skálová A](https://www.ncbi.nlm.nih.gov/pubmed/?term=Sk%C3%A1lov%C3%A1%20A%5BAuthor%5D&cauthor=true&cauthor_uid=28614209), [Gnepp DR](https://www.ncbi.nlm.nih.gov/pubmed/?term=Gnepp%20DR%5BAuthor%5D&cauthor=true&cauthor_uid=28614209), [Lewis JS Jr](https://www.ncbi.nlm.nih.gov/pubmed/?term=Lewis%20JS%20Jr%5BAuthor%5D&cauthor=true&cauthor_uid=28614209), [Hunt JL](https://www.ncbi.nlm.nih.gov/pubmed/?term=Hunt%20JL%5BAuthor%5D&cauthor=true&cauthor_uid=28614209), [Bishop JA](https://www.ncbi.nlm.nih.gov/pubmed/?term=Bishop%20JA%5BAuthor%5D&cauthor=true&cauthor_uid=28614209), [Hellquist H](https://www.ncbi.nlm.nih.gov/pubmed/?term=Hellquist%20H%5BAuthor%5D&cauthor=true&cauthor_uid=28614209), et al. Newly Described

Entities in Salivary Gland Pathology. [Am J Surg Pathol.](https://www.ncbi.nlm.nih.gov/pubmed/?term=28614209) 2017, 41:e33-e47. https://doi:

10.1097/PAS.0000000000000883.

[2] Schmitt NC, Kang H, Sharma A. Salivary duct carcinoma: An aggressive salivary gland malignancy

with opportunities for targeted therapy. Oral Oncol. 2017; 74:40-48. https://doi:

10.1016/j.oraloncology.2017.09.008.

[3] M.W. Han, J.L. Roh, S.H. Choi, S.Y. Nam, H.J. Lee, K.J. Cho, et al **Prognostic factors and**

**outcome analysis of salivary duct carcinoma.** Auris Nasus Larynx, 2015, 42: 472-477.

<https://doi.org/10.1016/j.anl.2015.04.005>

[4] Laine M, Bläuer M, Ylikomi T, Tuohimaa P, Aitasalo K, Happonen RP, et al. Immunohistochemical

demonstration of androgen receptors in human salivary glands. Arch Oral Biol. 1993; 38: 299-302.

[https://doi.org/10.1016/0003-9969(93)90136-A](https://doi.org/10.1016/0003-9969%2893%2990136-A)

[5] Urban D, Rischin D, Angel C, D'Costa, Solomon B. Abiraterone in metastatic salivary duct

carcinoma. J Natl Compr Canc Netw. 2015; 13:288-90.

[https://www.ncbi.nlm.nih.gov/pubmed/25736005](https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&uact=8&ved=2ahUKEwix57CFiPDfAhUk5uAKHVMqDd4QFjAAegQIARAB&url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpubmed%2F25736005&usg=AOvVaw0wrH764wP8Jgyr4OECI4fi)

[6] Lomax A J, Beith J, Bhadri V, Boyer M, Grimison P, Horvath LG, et al. Outcomes of patients with non-melanoma solid tumours receiving self-funded pembrolizumab [at Chris O'Brien Lifehouse.](https://www.ncbi.nlm.nih.gov/pubmed/27554283)

Intern Med J. 2016; 46:1392-1398. https://doi: 10.1111/imj.13232.

[7] Dalgleish A G, Stebbing J, Adamson DJ, Arif SS, Bidoli P, Chang D et al. Randomised, open-

label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer. Br

J Cancer. 2016;115:e16. https://doi: 10.1038/bjc.2016.271.

[8] Correa T S, Matos G D, Segura M, Dos Anjos C H. Second-Line Treatment of HER2-Positive

Salivary Gland Tumor: Ado-Trastuzumab Emtansine (T-DM1) after Progression on Trastuzumab.

Case Rep Oncol. 2018; 11:252-257. https://doi: [10.1159/000488669](https://dx.doi.org/10.1159/000488669).

# [9] [Cohen RB](https://www.ncbi.nlm.nih.gov/pubmed/?term=Cohen%20RB%5BAuthor%5D&cauthor=true&cauthor_uid=29462123), [Delord JP](https://www.ncbi.nlm.nih.gov/pubmed/?term=Delord%20JP%5BAuthor%5D&cauthor=true&cauthor_uid=29462123), [Doi T](https://www.ncbi.nlm.nih.gov/pubmed/?term=Doi%20T%5BAuthor%5D&cauthor=true&cauthor_uid=29462123), [Piha-Paul SA](https://www.ncbi.nlm.nih.gov/pubmed/?term=Piha-Paul%20SA%5BAuthor%5D&cauthor=true&cauthor_uid=29462123), [Liu SV](https://www.ncbi.nlm.nih.gov/pubmed/?term=Liu%20SV%5BAuthor%5D&cauthor=true&cauthor_uid=29462123), [Gilbert J](https://www.ncbi.nlm.nih.gov/pubmed/?term=Gilbert%20J%5BAuthor%5D&cauthor=true&cauthor_uid=29462123) et al. Pembrolizumab for the

# Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028

# Study. Am J Clin Oncol 2018 ;41:1083-1088. https://doi: 10.1097/COC.0000000000000429.

**Figure legends**

Figure 1: Serial CT assessment of lytic skeletal metastases. Initial assessment (a) demonstrates multiple lytic skeletal metastases demonstrated in the iliac bones. Six months later, after four courses of Carboplatin and Paclitaxel, interval CT assessment (b) demonstrates progressive disease with increase in size of lytic skeletal metastases as well as a new lesion in the sacrum on this image. First post-assessment CT (c) after 2 months of Abiraterone therapy demonstrates stable size of bony metastases with internal and marginal sclerosis seen reflecting the early features of bone healing. An assessment study at 1 year (d) demonstrates further increased sclerosis of bone lesions reflecting bone healing as well as sclerosis of prior subtle/occult metastases.

Figure 2: Baseline 18F-FDG PET/CT assessment (figure a) demonstrating widespread skeletal metastases in the vertebra, ribs and pelvis on a sagittal maximum intensity projection of the PET component. This demonstrates a partial metabolic response at 3 month post treatment assessment (figure b) with a complete metabolic response at 6 month post –treatment assessment (figure c).

Figure 3: Pre-treatment (a-c) and 6 month post-treatment (d-f) assessment 18F-FDG PET/CT studies (a, d – 3mm axial CT; b, e – 3mm fusion axial PET/CT and c, f – axial PET) demonstrating a partial response after commencement of Bicalutamide. FDG avid disease is seen within the T12 vertebral body extending into the left pedicle on pre-treatment study with very subtle lucency on the CT study. Post- treatment scan demonstrates a marked reduction into FDG activity with patchy marginal sclerosis on the CT scan.

Figure 4: Core biopsy of left iliac crest showing (a) a myxoid and epithelial tumour with characteristic features of Metastasizing Pleomoprhic Adenoma (MPA). Low power view 10X

(b)Higher magnifications showing small sized ducts lined by cells with ample and eosinophilic cytoplasm indicating oncocytic differentiation. 40x. (c) Immunohistochemistry for androgen receptor. Strong nuclear staining is seen in the majority of ductal cells. 40X

Figure 5: Baseline CT (a, d) demonstrate pulmonary metastases in the left lower lobe (solid arrow) and left upper lobe (open arrow) respectively. After 4 months Bicalutamide therapy (b, e) there has been a partial response to treatment. Continued response is seen at 10 months post Bicalutamide therapy (c, f).